August 11, 2017

Siemens Healthcare Diagnostics  
Gerard Sadrakula  
Regulatory Affairs Specialist  
511 Benedict Avenue  
Tarrytown, NY 10591

Re: K162977
Trade/Device Name: ADVIA® 2120
           ADVIA® 2120i
Regulation Number: 21 CFR 864.5220
Regulation Name: Automated Differential Cell Counter
Regulatory Class: Class II
Product Code: GKZ
Dated: August 9, 2017
Received: August 11, 2017

Dear Mr. Sadrakula:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address [http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm](http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm). Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to [http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm](http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm) for the CDRH’s Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address [http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm](http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm).

Sincerely,

Leonthena R. Carrington -S

Lea Carrington
Director
Division of Immunology and Hematology Devices
Office of *In Vitro* Diagnostics and Radiological Health
Center for Devices and Radiological Health

Enclosure
Continuing on a separate page if needed.

Prescription use (Part I 21 CFR 801 Subpart C)

Type of use (Select one of both, as applicable):


In addition, the system provides the added capability to automatically prepare and stain high quality blood smears on a

4. Qualitative determination of blood cells in cerebrospinal fluid (CSF) consisting of WBC, RBC, Neutrophils (PMN), Lymphocytes, Monocytes (MO), and/or CD8+ T lymphocytes.

Necropsy Above mentioned are determined (in whole blood, plasma, peripheral or portal blood samples) with K2

5. Hemoglobin (HGB), MCV, MCH, MCHC, HDW, and/or MPV.

6. macrophage, PMN, eosinophils, lymphocytes, monocytes, and T lymphocytes.

7. The ADVIA 2120 and ADVIA 2120i with a slide and a microscope, and a label to indicate the

Indications for Use (described)

ADVIA 2120/2120i Hematology

Device Name

K163277

Sto(2) Number (if known)

Indications for Use

Food and Drug Administration

DEPARTMENT OF HEALTH AND HUMAN SERVICES

See PRA statement below.

Expiration date: January 31, 2017

From approved: ONB NO. 0910-0120
1.10A 510k Summary

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR §807.92.

510(k) Number:  K162977

Date of Preparation: October 19th, 2016. Updated: July 13th 2017

Proprietary and Established Names:

ADVIA®120,
ADVIA®2120,
ADVIA®2120i,

Applicant:

Siemens Healthcare Diagnostics Inc.,
511 Benedict Ave, Tarrytown, NY 10591
Gerard Sadrakula, Regulatory Affairs Specialist
Office: (914) 524-2582
Fax: (914) 524-3579

Regulatory Information:

The ADVIA®2120i is a class 2 analyzer that produces no PMA results.

Predicate Devices:

ADVIA®2120 cleared in k102644
ADVIA®2120i cleared in k102644

Device Description:

The ADVIA 2120i (RoHS/REACH compliant) is a modification of the ADVIA 2120i Hematology System designed to address the following business needs:

- To achieve RoHS & Reach compliance
- To address component obsolescence
Intended Use / Indications for Use:

The ADVIA 2120 and 2120i with autoslide are quantitative, automated hematology analyzers that provide the following information for in vitro diagnostic use in clinical laboratories:

- A complete blood count (CBC) consisting of WBC, RBC, Hgb, CN-Free Hgb, Calculated Hgb, MCV, Hct, MCH, MCHC, CHCM, RDW, HDW, CH, Plt, MPV.
- A leukocyte differential count consisting of: Neut (%/#), Lymph (%/#), Mono (%/#), Eos (%/#), Baso (%/#), LUC (%/#).
- A reticulocyte analysis consisting of Retic (%/#), MCVg, MCVr, CHCMg, CHCMr, CHg, CHr.
- A nucleated red blood cell count consisting of NRBC (%/#).
- Enumeration of the total nucleated cell (TNC) count and RBC count for pleural, peritoneal, and peritoneal dialysis (PD) specimens.

Note: Above measurands are determined (in whole blood, pleural, peritoneal, or peritoneal dialysis specimens) with K2 and/or K3 EDTA anti-coagulants.

- Quantitative determination of blood cells in Cerebrospinal Fluid (CSF) consisting of WBC, RBC, Neut (%/#), Lymph (%/#), Mono (%/#), MN (%/#), PMN (%/#).

In addition, the system provides the added capability to automatically prepare and stain high quality blood smears on a glass microscope slide.
## Technology Features Comparison Table

<table>
<thead>
<tr>
<th>Feature</th>
<th>ADVIA 2120i</th>
<th>ADVIA 2120i (RoHS/REACH Compliant)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type of System</strong></td>
<td>Stand-alone, mid-high volume hematology analyzer</td>
<td>Same</td>
</tr>
<tr>
<td><strong>Throughput Rate</strong></td>
<td>120 samples/hour</td>
<td>Same</td>
</tr>
<tr>
<td><strong>Intended Use</strong></td>
<td>Quantitative, automated hematology analyzers that provide information for in vitro diagnostic use in clinical laboratories</td>
<td>Same</td>
</tr>
<tr>
<td><strong>Sample Type</strong></td>
<td>whole blood, pleural, peritoneal, or peritoneal dialysis specimens with K2 and/or K3 EDTA anti-coagulants</td>
<td>Same</td>
</tr>
<tr>
<td><strong>Sample volume</strong></td>
<td>175ul</td>
<td>Same</td>
</tr>
<tr>
<td><strong>Reagents</strong></td>
<td>Reagents to support Complete Blood Count, White Blood Cell differential and Reticulocyte analysis</td>
<td>Same</td>
</tr>
<tr>
<td><strong>Modes of sampling</strong></td>
<td>3 sampling modes: Manual open tube sampler, manual closed tube sampler and automated closed tube sampler (autosampler).</td>
<td>Same</td>
</tr>
<tr>
<td><strong>Data Entry</strong></td>
<td>Keyboard and Touch Screen Monitor</td>
<td>Same</td>
</tr>
<tr>
<td><strong>Bar code reading capability</strong></td>
<td>Fixed and Handheld bar code readers</td>
<td>Same</td>
</tr>
<tr>
<td><strong>Operating Principals</strong></td>
<td>Flow cytometry, RBC lysing, myeloperoxidase staining of the WBCs and oxazine staining of the reticulocytes, using five channels to analyze blood samples.</td>
<td>Same</td>
</tr>
<tr>
<td><strong>Controls</strong></td>
<td>ADVIA 3 in 1 with retics (Normal, Abnormal 1, Abnormal 2) or CBC only (L,N,H) and reticulocytes (L, H)</td>
<td>Same</td>
</tr>
<tr>
<td><strong>Calibrator</strong></td>
<td>Commercially available calibrator</td>
<td>Same</td>
</tr>
<tr>
<td><strong>Automation Interface Software</strong></td>
<td>Interface software to allow connection to LabCell or Aptio automation</td>
<td>Same</td>
</tr>
<tr>
<td><strong>Software</strong></td>
<td>Clinical- V6.2.4</td>
<td>Same</td>
</tr>
<tr>
<td><strong>CPU Module</strong></td>
<td>ARM 9 CPU Module</td>
<td>Same</td>
</tr>
<tr>
<td>Feature</td>
<td>ADVIA 2120i</td>
<td>ADVIA 2120i (RoHS/REACH Compliant)</td>
</tr>
<tr>
<td>------------------------------</td>
<td>-----------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Signal Processor PCB</td>
<td>Existing non-RoHS compliant Signal Processing PCB. No onboard software</td>
<td>New VHDL implementation of signal processing and monitor/keyboard interface design, to achieve RoHS compliance. No onboard software.</td>
</tr>
<tr>
<td>Autosampler Control PCB DAA</td>
<td>Dropped in SMC4 motor controller. Onboard motion control software for 80186 (CPU).</td>
<td>New VHDL implementation of former used discrete components and includes SMC4 motor control. No change to predicate software.</td>
</tr>
<tr>
<td>Autosampler Control PCB SAA</td>
<td>Dropped in SMC4 motor controller. Onboard motion control software for 80186 (CPU).</td>
<td>New VHDL implementation of former used discrete components and includes SMC4 motor control. No change to predicate software.</td>
</tr>
<tr>
<td>Reference preAmplifier</td>
<td>No onboard software or firmware. Contains some non-RoHS compliant components.</td>
<td>No onboard software or firmware. Uses the predicate sensors.</td>
</tr>
<tr>
<td>PreAmp Power Supply</td>
<td>No onboard software or firmware. Contains some non-RoHS compliant components.</td>
<td>No onboard software or firmware. Uses the predicate sensors.</td>
</tr>
<tr>
<td>Laser Diode Driver 1</td>
<td>No onboard software or firmware. Contains some non-RoHS compliant components.</td>
<td>No onboard software or firmware. Contains some minor RoHS component changes.</td>
</tr>
<tr>
<td>Dual Servo Pump</td>
<td>Uses original Software</td>
<td>New VHDL implementation of former used discrete components. Uses original Software.</td>
</tr>
<tr>
<td>Valve Driver Board</td>
<td>Uses original Software</td>
<td>New VHDL implementation of former used discrete components. Uses original Software.</td>
</tr>
<tr>
<td>Parallel Node</td>
<td>Uses original Software</td>
<td>New VHDL implementation of former used discrete components. Uses original Software.</td>
</tr>
<tr>
<td>HGB Interface</td>
<td>Uses original Software</td>
<td>New VHDL implementation of former used discrete components. Uses original Software.</td>
</tr>
<tr>
<td>Perox Optics Scrambler</td>
<td>No onboard software or firmware. Contains some non-RoHS compliant components.</td>
<td>No onboard software or firmware. Contains some minor RoHS component changes.</td>
</tr>
<tr>
<td>Sensor Amplifier</td>
<td>No onboard software or firmware. Contains some non-RoHS compliant components.</td>
<td>No onboard software or firmware. Contains some minor RoHS component changes.</td>
</tr>
<tr>
<td>Rack Sensor LED</td>
<td>No onboard software or firmware. Contains some non-RoHS compliant components.</td>
<td>No onboard software or firmware. Contains some minor RoHS component changes.</td>
</tr>
<tr>
<td>Component</td>
<td>Description</td>
<td>Status</td>
</tr>
<tr>
<td>----------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Indicator Assy DAA</td>
<td>No onboard software or firmware. Contains some non-RoHS compliant components.</td>
<td>No onboard software or firmware. Contains some minor RoHS component changes.</td>
</tr>
<tr>
<td>Indicator Assy SAA</td>
<td>Interconnect board. No onboard software or firmware. Contains some non-RoHS compliant components.</td>
<td>No onboard software or firmware. Contains some minor RoHS component changes.</td>
</tr>
<tr>
<td>Input/Output Q I/O PCBA</td>
<td>Interconnect board. No onboard software or firmware. Contains some non-RoHS compliant components.</td>
<td>No onboard software or firmware. Contains some minor RoHS component changes.</td>
</tr>
<tr>
<td>CAN Scrambler</td>
<td>Interconnect board. No onboard software or firmware. Contains some non-RoHS compliant components.</td>
<td>No onboard software or firmware. Contains some minor RoHS component changes.</td>
</tr>
<tr>
<td>Baso Optics Scrambler</td>
<td>Interconnect board. No onboard software or firmware. Contains some non-RoHS compliant components.</td>
<td>No onboard software or firmware. Contains some minor RoHS component changes.</td>
</tr>
<tr>
<td>Pneu Valve Scrambler Board</td>
<td>Interconnect board. No onboard software or firmware. Contains some non-RoHS compliant components.</td>
<td>No onboard software or firmware. Contains some minor RoHS component changes.</td>
</tr>
<tr>
<td>UFC Illumination Board</td>
<td>Provides cosmetic lighting. No onboard software or firmware. Contains some non-RoHS compliant components.</td>
<td>No onboard software or firmware. Contains some minor RoHS component changes.</td>
</tr>
<tr>
<td>Switch Panel Interface</td>
<td>Interconnect board. No onboard software or firmware. Contains some non-RoHS compliant components.</td>
<td>No onboard software or firmware. Contains some minor RoHS component changes.</td>
</tr>
<tr>
<td>ID Reader Interface</td>
<td>Interconnect board. No onboard software or firmware. Contains some non-RoHS compliant components.</td>
<td>No onboard software or firmware. Contains some minor RoHS component changes.</td>
</tr>
<tr>
<td>UFC Valve Scrambler PCB</td>
<td>Interconnect board. No onboard software or firmware. Contains some non-RoHS compliant components.</td>
<td>No onboard software or firmware. Contains some minor RoHS component changes.</td>
</tr>
</tbody>
</table>
Standard/Guidance Document Referenced:

- EN 61010-1:2010 - Safety requirements for electrical equipment for measurement, control, and laboratory use - Part 1: General Requirements
- EN 61010-1:2010, Safety requirements for electrical equipment for measurement, control, and laboratory use - Parts 2-6: Particular Requirements – In vitro diagnostic (IVD) medical equipment
- IEC 62366:2008 - Medical devices - Application of usability engineering to medical devices

Note: Regarding Standards IEC 62366:2008 no summary report is being supplied. As detailed in section 1.10 Technology Features Comparison Table, “There are no usability changes to the ADVIA 2120i and the ADVIA 2120i (RoHS/REACH compliant system). Therefore the usability file was updated however no separate report has been created. Existing ADVIA 2120i usability has already been approved as part of the prior 510(k102644) submission.

- EN 62304:2006/AC:2008 - Medical device software - Software life-cycle processes
- EN ISO 15223-1:2012 Medical devices - symbols to be used with medical device labels, labeling and information to be supplied

Note: Regarding Standard EN. ISO 15223-1:2012 no summary report is being supplied. As stated in the Operator guide section 2.7, “There are no Major changes to the ADVIA 120/2120/2120i Operators Guide and the Supplemental Information Research Use Only (RUO) Guide, just some minor formatting and administrative changes to these guides”. Therefore as the original Guides have already been approved as part of the prior 510(k102644) submission.
1.12 Performance Characteristics:

The methods listed below:
  a. Basophil/Lobularity Method
  b. CSF Method
  c. Hemoglobin Method
  d. Peroxidase Method
  e. RBC/Platelet Method
  f. Reticulocyte Method
  g. Body Fluids Method

Had the following studies completed **internally** via the following sections of this submission:
  7.1 Carryover
  7.2 Linearity
  7.3 Imprecision (within run)
  7.4 Accuracy
  7.5 Commercial Controls Repeatability and within device Imprecision
  7.6 Limit of Quantitation/Detection/Blank

These studies show performance equivalence of the ADVIA®2120i (RoHS/REACH compliant) against the ADVIA®2120 and 2120i. The protocols were tested using CBC, CBC/DIFF, CBC/DIFF/RETIC and Retic only selectivities in each of the sampling modes; opened tube sampling, manual closed tube sampling and automated closed-tube sampling. No non-conformances were observed.

The methods listed below:
  a. Body Fluid
  b. CSF Accuracy

Had the following studies completed at **external** Clinical sites via sections 8.1 of this submission:
  CSF and Body Fluid Accuracy
  System Flagging and Method Validation

These studies show performance equivalence of the ADVIA®2120i (RoHS/REACH compliant) against the ADVIA®2120 and 2120i as tested at these External Sites:
  - “University of California-San Francisco”
  - “Siemens Healthcare Diagnostics”
  - “Memorial Sloan-Kettering Cancer Center”
No non-conformances were observed.

There is no change for user needs and intended use in this project. Our overall conclusion is that:
As a result the ADVIA 2120i Hematology RoHS/REACH analyzer is safe and effective and performs clinically equivalent to the predicate device